Abstract 2168: Anti-cancer drug sensitivity assay using in vitro primary culture cells

Abstract

Abstract Primary culture of cancer cells derived from an individual patient's tumor provides important information regarding the tumor character. We established a novel culture method for primary colorectal cancer (CRC) with phenotypic heterogeneity as a human tumor model, named isolated tumor-derived cancer cells (iCCs). The success rate of iCC growth in vitro was 100%, passage was 90%, and establishment of a xenograft model from iCC was 80%. The gene expression of the cultured cells was similar to the clinical tumors, and exhibited a ductal structure of the tumor in the xenograft model even after several passages. The present in vitro analyses allow us to predict the clinical efficacy of chemotherapeutic drugs. For this purpose, we examined the sensitivities of iCCs isolated from patients. In this study four patients with distant metastasis received FOLFOX (folinic acid, 5-fluorouracil, and oxaliplatin) chemotherapy according to the treatment guidelines, and in vitro drug sensitivity was evaluated using the cultured cells, compared with each parental tumor in the individual clinical course. It is a model to predict the effect of chemotherapy to the individual tumor. Our results showed that the effect of chemotherapy was poor in three patients and good in one patient. In their clinical courses, the tumor size increased in two patients and decreased in two patients. In vitro drug sensitivity results reflected the clinical course in three of the four patients. In conclusion, our primary culture model is a novel tool for the prediction of anti-cancer drugs in the clinical courses. Citation Format: Shiki Fujino, Norikatsu Miyoshi, Masayuki Ohue, Kazuhiro Saso, Tsunekazu Mizushima, Yuichiro Doki, Masaki Mori. Anti-cancer drug sensitivity assay using in vitro primary culture cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 2168.